SAN DIEGO - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC) shared promising data from a Phase 1b trial of LYT-200, a novel anti-galectin-9 monoclonal antibody, at the American Society of Hematology (ASH) Annual Meeting. The trial involved patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), showing the drug's safety and efficacy both as a standalone treatment and in combination with current standard-of-care therapies.
Patients with AML/MDS who have relapsed or shown resistance to prior treatments received LYT-200 in varying doses. Results indicated that 59% of evaluable patients achieved stable disease or better, with two partial responses noted. The average duration of treatment was over two months, surpassing the standard survival rate for patients resistant to venetoclax and hypomethylating agents (HMA).
In combination with venetoclax/HMA, LYT-200 showed an 80% rate of stable disease or better, with two complete responses and one morphologic leukemia-free state. The combination treatment also benefited patients with specific mutations like KRAS/NRAS, supporting the potential of LYT-200 to enhance the efficacy of existing AML treatments.
LYT-200's dual-action mechanism was highlighted, which includes direct cancer cell apoptosis and re-activation of the immune system's anti-cancer effectors. Pharmacodynamic assessments further validated this dual mode of action, identifying cellular pathways and immune cell types that may be key to the drug's response.
Based on these findings, PureTech plans to advance LYT-200 into a Phase 2 clinical trial, positioning it as a potential first-line treatment for AML/MDS patients. The company, which focuses on developing medicines for devastating diseases, has previously indicated that LYT-200 will be developed through its Founded Entity, Gallop Oncology.
The data presented is based on a press release statement from PureTech Health plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.